Technology
Health
Biotechnology

Entasis Therapeutics

$6.66
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.24 (-3.45%) Today
-$0.06 (-0.89%) After Hours

Why Robinhood?

You can buy or sell ETTX and other stocks, options, ETFs, and crypto commission-free!

About

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. Read More The company is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in March 2018 and is headquartered in Waltham, MA.

Employees
31
Headquarters
Waltham, Massachusetts
Founded
2018
Market Cap
88.02M
Price-Earnings Ratio
Dividend Yield
Average Volume
60.80K
High Today
$6.93
Low Today
$6.71
Open Price
$6.91
Volume
2.81K
52 Week High
$13.70
52 Week Low
$3.97

Collections

Technology
Health
Biotechnology
Therapy
Medical
Biopharmaceutical
Pharmaceutical
2018 IPO

News

Associated PressMar 6

Entasis Therapeutics to Present at the 39th Annual Cowen Healthcare Conference

This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. WALTHAM, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today a...

18

Earnings

-$20.00
-$13.60
-$7.20
-$0.80
Q3 2018
Q4 2018
Estimated
-$0.80 per share
Actual
Expected Mar 25, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.